Supernus Pharmaceuticals Inc (SUPN) Stake Decreased by Royce & Associates LP
Royce & Associates LP reduced its holdings in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 37.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 99,000 shares of the specialty pharmaceutical company’s stock after selling 60,000 shares during the quarter. Royce & Associates LP’s holdings in Supernus Pharmaceuticals were worth $3,945,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of SUPN. The Manufacturers Life Insurance Company grew its position in shares of Supernus Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after buying an additional 128 shares during the last quarter. Nationwide Fund Advisors lifted its stake in shares of Supernus Pharmaceuticals by 240.1% in the 3rd quarter. Nationwide Fund Advisors now owns 242,691 shares of the specialty pharmaceutical company’s stock valued at $9,708,000 after purchasing an additional 171,341 shares during the period. First Trust Advisors LP purchased a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at approximately $2,255,000. Pictet Asset Management Ltd. lifted its stake in shares of Supernus Pharmaceuticals by 438.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after purchasing an additional 400,083 shares during the period. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at approximately $858,000. Hedge funds and other institutional investors own 98.37% of the company’s stock.
A number of research firms have recently commented on SUPN. ValuEngine upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Berenberg Bank began coverage on Supernus Pharmaceuticals in a research note on Thursday, February 1st. They issued a “buy” rating and a $66.00 target price for the company. BidaskClub cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. B. Riley restated a “buy” rating and issued a $54.00 target price on shares of Supernus Pharmaceuticals in a research note on Thursday, January 18th. Finally, Zacks Investment Research cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $51.36.
Supernus Pharmaceuticals Inc (NASDAQ SUPN) opened at $39.65 on Friday. The stock has a market capitalization of $1,997.06, a price-to-earnings ratio of 31.25 and a beta of 1.07. Supernus Pharmaceuticals Inc has a one year low of $25.00 and a one year high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 29.24% and a net margin of 18.95%. The business’s revenue was up 41.5% compared to the same quarter last year. analysts expect that Supernus Pharmaceuticals Inc will post 1.58 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/03/03/supernus-pharmaceuticals-inc-supn-stake-decreased-by-royce-associates-lp.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.